Home › All Companies › ANRO › Annual Report

Alto Neuroscience, Inc. (ANRO) — Annual Report

AI-Powered SEC Filing Analysis

← All ANRO filings
Latest Annual Report Filed: 2026-03-16

Key Insights

  • The company reported a net loss of $44.962 million for the fiscal year 2025, indicating continued significant investment in research and development for its clinical-stage assets.
  • Alto Neuroscience raised $379 million in gross proceeds from an IPO in 2024, providing a strong cash position to advance its pipeline.
  • The company has secured various debt financing agreements, including a loan and security agreement and an amended loan agreement, to support its operations and development activities.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Alto Neuroscience, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.